Internal Medicine, Endocrinology, Diabetes, & Metabolism · Houston, TX
NPI
1891155099
Since 2016
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
10837 Katy Fwy Ste 200
Houston, TX, 77079
Phone (832) 649-4386
Groups this clinician bills Medicare through
Medicare paid, 2024
$35K
1,780 services
Medicare patients, 2024
111
Average age 70
Drug cost, 2024
$441K
1,030 prescriptions
Company payments, 2025
$294
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adele Amine was code 36415 (venipuncture blood collection), 109 times for 66 patients. In total Adele Amine billed 1,780 services in 17 codes, and Medicare paid $35K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 109 | 66 | $8.50 | $927 |
| 99213 Office E&M - Established | Office | 83 | 66 | $60.49 | $5,020 |
| 99214 Office E&M - Established | Office | 49 | 33 | $91.01 | $4,459 |
| 99203 Office E&M - New | Office | 29 | 29 | $70.99 | $2,059 |
| 96372 Injection Administration | Office | 18 | 13 | $9.70 | $175 |
By year: 2022 $108K for 5,000 services; 2023 $16K for 474 services; 2024 $35K for 1,780 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 109 | 66 | $8.50 | $927 |
Medicare prescription drug claims, 2024
In 2024, the drug Adele Amine prescribed most often to Medicare patients was Levothyroxine Sodium, with 127 prescriptions and refills. In total Adele Amine wrote 1,030 Medicare prescriptions that cost $441K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 127 | 251 | 34 | $48K |
| Metformin Hcl Generic | 46 | 74 | 11 | $549 |
| Jardiance Empagliflozin | 45 | 95 | 17 | $56K |
| Methimazole Generic | 44 | 82 | 11 | $345 |
| Ozempic Semaglutide | 43 | 67 | 12 | $60K |
| Alendronate Sodium Generic | 43 | 117 | 19 | $527 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 42 | 95 | 22 | $5,496 |
| Humalog Kwikpen U-100 Insulin Lispro | 32 | 63 | 13 | $10K |
| Trulicity Dulaglutide | 30 | 43 | 14 | $41K |
| Metformin Hcl Er Metformin Hcl | 28 | 76 | 11 | $286 |
| Synthroid Levothyroxine Sodium | 26 | 73 | Under 11 | $2,025 |
| Mounjaro Tirzepatide | 25 | 25 | Under 11 | $26K |
| Tresiba Flextouch U-100 Insulin Degludec | 25 | 52 | Under 11 | $15K |
| Rybelsus Semaglutide | 23 | 31 | Under 11 | $27K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 23 | 56 | 11 | $3,055 |
Brand drugs: 526 claims; generic drugs: 419 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adele Amine $294 ($294 in general payments such as food, travel and fees) from 7 companies. The largest payer was Insulet Corporation with $127.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.